Creatine Monohydrate: What Does the ISSN Position Stand Actually Conclude?

The short answer

The 2017 International Society of Sports Nutrition (ISSN) position stand, led by Richard B. Kreider and published in the Journal of the International Society of Sports Nutrition, reaches a confident verdict on one point: creatine monohydrate is the most effective researched nutritional supplement for increasing high-intensity exercise capacity and lean body mass during training. It also concludes that creatine has a strong documented safety record at the doses studied. Its statements about clinical and neuroprotective uses are written far more cautiously, and reading the document well means noticing where the confident language stops and the hedged language begins.

What a position stand is, and how to read one

A position stand is not a single trial. It is a society's structured synthesis of a large body of published work, written by a panel and meant to represent a consensus reading of the evidence. That format has a specific strength and a specific weakness. The strength is breadth: the ISSN document draws on decades of creatine research across hundreds of studies. The weakness is that a consensus statement blends findings of very different quality, so the confident summary sentences can flatten the distinction between a claim resting on dozens of randomized trials and a claim resting on a handful of animal models or small pilot studies.

The practical skill is to read each conclusion and ask what sits underneath it. In the creatine document, some statements are backed by an unusually deep and consistent literature. Others are framed as areas that warrant further research, which is the polite scientific phrasing for a hypothesis that is interesting but unproven.

The strong claim: performance and lean mass

Here the evidence is deep, and the position stand says so plainly. Its headline conclusion is that creatine monohydrate is the most effective ergogenic nutritional supplement currently available to athletes who want to increase high-intensity exercise capacity and lean body mass during training. The proposed mechanism is straightforward and well characterized. Supplementation raises the concentration of phosphocreatine stored in muscle, which supports the rapid regeneration of adenosine triphosphate during short, intense efforts. More available energy for repeated hard bouts allows more work per session, and more work over weeks tends to produce greater training adaptations.

Two caveats keep this from being a blanket promise. First, the benefit is concentrated in short-duration, high-intensity, repeated-effort activities, such as sprints and resistance training, and is much less relevant to steady endurance work. Second, the lean-mass gain in the first days of supplementation reflects, in part, water drawn into muscle, alongside genuine gains in training-driven muscle protein over longer periods. The direction of the effect is well established across many controlled studies; the magnitude varies by individual, baseline creatine status, and diet, with vegetarians who start with lower muscle stores often responding more.

The safety record, and the kidney misconception

The position stand's safety conclusion is similarly grounded. It reports no compelling scientific evidence that short- or long-term use of creatine monohydrate, at intakes up to 30 grams per day for as long as five years, produces detrimental effects in healthy people. It notes that clinical populations have been given high doses, on the order of 0.3 to 0.8 grams per kilogram per day, for extended periods without serious adverse events being attributed to the supplement.

The most useful thing the document clears up is a persistent misreading of a lab value. Creatine is metabolized to creatinine, and serum creatinine is the number clinicians use to estimate kidney function. Supplementation can nudge that marker upward simply because more creatinine is being produced, not because the kidney is failing to clear it. The position stand states there is no compelling evidence that creatine supplementation harms renal function in healthy individuals. That is a statement about a studied population, not a universal clearance for everyone. Someone with existing kidney disease, or who is pregnant, or who takes other medications is outside the groups these safety data describe, and that is a decision to make individually with a treating clinician rather than from a supplement label.

The weaker claims: clinical and neuroprotective uses

This is where careful reading matters most. The same document that speaks firmly about performance shifts into conditional language when it turns to medicine. It raises possible roles for creatine in recovery, injury prevention, thermoregulation, rehabilitation, and neuroprotection after concussion or spinal cord injury, and it points toward metabolic and neurodegenerative conditions. But it frames these as areas needing further research rather than as established therapeutic uses.

The underlying evidence explains the tone. Support for neuroprotection is strongest in animal models of traumatic brain injury and much thinner for human neurodegenerative disease. Large trials in Parkinson's disease, for example, have not delivered the benefit that early mechanistic reasoning suggested. So the honest way to read the clinical section is that it catalogs plausible directions supported by preliminary data, not treatments a reader should expect to work. A promising signal in a preclinical model is a reason to run a proper trial, not a reason to act as though the trial already succeeded.

This article is educational and is not medical advice. When a position stand uses confident language for one claim and hedged language for another, that contrast is information, and it usually reflects a real gap in the quality of the evidence rather than mere authorial caution.

The takeaway

The ISSN creatine position stand is a useful case study in how to read any society document. Match the strength of each claim to the strength of the evidence beneath it. For high-intensity performance and lean mass, and for baseline safety at the studied doses, the creatine literature is broad and consistent, and the stand says so. For clinical and neuroprotective applications, the same stand deliberately softens its language, and a careful reader should soften expectations to match.